These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 36975811)
1. Effective Colonization by Nontoxigenic Clostridioides difficile REA Strain M3 (NTCD-M3) Spores following Treatment with Either Fidaxomicin or Vancomycin. Sambol SP; Skinner AM; Serna-Perez F; Owen B; Gerding DN; Johnson S Microbiol Spectr; 2023 Mar; 11(2):e0051723. PubMed ID: 36975811 [TBL] [Abstract][Full Text] [Related]
2. Non-toxigenic Gerding DN; Sambol SP; Johnson S Front Microbiol; 2018; 9():1700. PubMed ID: 30093897 [TBL] [Abstract][Full Text] [Related]
3. Administration of spores of nontoxigenic Clostridium difficile strain M3 for prevention of recurrent C. difficile infection: a randomized clinical trial. Gerding DN; Meyer T; Lee C; Cohen SH; Murthy UK; Poirier A; Van Schooneveld TC; Pardi DS; Ramos A; Barron MA; Chen H; Villano S JAMA; 2015 May; 313(17):1719-27. PubMed ID: 25942722 [TBL] [Abstract][Full Text] [Related]
4. Evaluation of an oral suspension of VP20621, spores of nontoxigenic Clostridium difficile strain M3, in healthy subjects. Villano SA; Seiberling M; Tatarowicz W; Monnot-Chase E; Gerding DN Antimicrob Agents Chemother; 2012 Oct; 56(10):5224-9. PubMed ID: 22850511 [TBL] [Abstract][Full Text] [Related]
5. Nontoxigenic Clostridium difficile protects hamsters against challenge with historic and epidemic strains of toxigenic BI/NAP1/027 C. difficile. Nagaro KJ; Phillips ST; Cheknis AK; Sambol SP; Zukowski WE; Johnson S; Gerding DN Antimicrob Agents Chemother; 2013 Nov; 57(11):5266-70. PubMed ID: 23939887 [TBL] [Abstract][Full Text] [Related]
6. Development of an Effective Nontoxigenic Clostridioides difficile-Based Oral Vaccine against C. difficile Infection. Wang S; Zhu D; Sun X Microbiol Spectr; 2022 Jun; 10(3):e0026322. PubMed ID: 35583336 [TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Fidaxomicin and Vancomycin in Children and Adolescents with Clostridioides (Clostridium) difficile Infection: A Phase 3, Multicenter, Randomized, Single-blind Clinical Trial (SUNSHINE). Wolf J; Kalocsai K; Fortuny C; Lazar S; Bosis S; Korczowski B; Petit A; Bradford D; Croos-Dabrera R; Incera E; Melis J; van Maanen R Clin Infect Dis; 2020 Dec; 71(10):2581-2588. PubMed ID: 31773143 [TBL] [Abstract][Full Text] [Related]
8. Fidaxomicin versus metronidazole, vancomycin and their combination for initial episode, first recurrence and severe Clostridioides difficile infection - An observational cohort study. Polivkova S; Krutova M; Capek V; Sykorova B; Benes J Int J Infect Dis; 2021 Feb; 103():226-233. PubMed ID: 33188906 [TBL] [Abstract][Full Text] [Related]
9. Relapse versus reinfection: recurrent Clostridium difficile infection following treatment with fidaxomicin or vancomycin. Figueroa I; Johnson S; Sambol SP; Goldstein EJ; Citron DM; Gerding DN Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S104-9. PubMed ID: 22752857 [TBL] [Abstract][Full Text] [Related]
10. Absence of toxin gene transfer from Clostridioides difficile strain 630Δerm to nontoxigenic C. difficile strain NTCD-M3r in filter mating experiments. Sambol SP; Johnson S; Cheknis A; Gerding DN PLoS One; 2022; 17(6):e0270119. PubMed ID: 35767545 [TBL] [Abstract][Full Text] [Related]
11. Antibiotic treatment for Clostridium difficile-associated diarrhoea in adults. Nelson RL; Suda KJ; Evans CT Cochrane Database Syst Rev; 2017 Mar; 3(3):CD004610. PubMed ID: 28257555 [TBL] [Abstract][Full Text] [Related]
12. Fidaxomicin preserves the intestinal microbiome during and after treatment of Clostridium difficile infection (CDI) and reduces both toxin reexpression and recurrence of CDI. Louie TJ; Cannon K; Byrne B; Emery J; Ward L; Eyben M; Krulicki W Clin Infect Dis; 2012 Aug; 55 Suppl 2(Suppl 2):S132-42. PubMed ID: 22752862 [TBL] [Abstract][Full Text] [Related]
13. Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States. Jiang Y; Sarpong EM; Sears P; Obi EN Infect Dis Ther; 2022 Feb; 11(1):111-126. PubMed ID: 34292496 [TBL] [Abstract][Full Text] [Related]
14. Fidaxomicin: a novel macrocyclic antibiotic for the treatment of Clostridium difficile infection. Crawford T; Huesgen E; Danziger L Am J Health Syst Pharm; 2012 Jun; 69(11):933-43. PubMed ID: 22610025 [TBL] [Abstract][Full Text] [Related]
15. Path of least recurrence: A systematic review and meta-analysis of fidaxomicin versus vancomycin for Clostridioides difficile infection. Liao JX; Appaneal HJ; Vicent ML; Vyas A; LaPlante KL Pharmacotherapy; 2022 Nov; 42(11):810-827. PubMed ID: 36223209 [TBL] [Abstract][Full Text] [Related]
16. SMT19969 for Clostridium difficile infection (CDI): in vivo efficacy compared with fidaxomicin and vancomycin in the hamster model of CDI. Sattar A; Thommes P; Payne L; Warn P; Vickers RJ J Antimicrob Chemother; 2015; 70(6):1757-62. PubMed ID: 25652749 [TBL] [Abstract][Full Text] [Related]
17. Comparison of fidaxomicin, metronidazole and vancomycin for initial episode and recurrence of Hernando-Gozalo M; Rescalvo-Casas C; Seijas-Pereda L; Cuadros-González J; Pérez-Tanoira R Heliyon; 2024 May; 10(10):e30742. PubMed ID: 38803946 [TBL] [Abstract][Full Text] [Related]
18. A Comparison of the Efficacy of Treatment With Fidaxomicin Versus Vancomycin in Clostridioides difficile Infection. Diaz-Pollan B; Carrasco Molina S; Marcelo C; de Gea Grela A; Martínez-Martín P; Jiménez-González M; Moreno Ramos F; Mora-Rillo M Cureus; 2023 Nov; 15(11):e48735. PubMed ID: 38094526 [TBL] [Abstract][Full Text] [Related]
19. The Risk of Hall RG; Cole TJ; Shaw C; Alvarez CA Antibiotics (Basel); 2022 Feb; 11(3):. PubMed ID: 35326759 [TBL] [Abstract][Full Text] [Related]
20. Real-World Budget Impact of Fidaxomicin versus Vancomycin or Metronidazole for In-Hospital Treatment of Clostridioides difficile Infection. Whitney L; Nesnas J; Planche T Antibiotics (Basel); 2023 Jan; 12(1):. PubMed ID: 36671306 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]